Cilostazol warnings and precautions: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Cilostazol}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARM..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Warnings And Precautions== | |||
{| | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref> | |<div style="background: WhiteSmoke; float: left; text-align: left; padding: 1em;"> | ||
'''''Cilostazol (PLETAL) and several of its metabolites are inhibitors of [[phosphodiesterase]] III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV [[congestive heart failure]]. PLETAL is contraindicated in patients with congestive heart failure of any severity.PLETAL is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding [[peptic ulcer]] and intracranial bleeding. PLETAL inhibits platelet aggregation in a reversible manner. PLETAL is contraindicated in patients with known or suspected [[hypersensitivity]] to any of its components<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref>''''' | |||
</div> | |||
|}<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Revision as of 00:01, 4 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Warnings And Precautions
Cilostazol (PLETAL) and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. PLETAL is contraindicated in patients with congestive heart failure of any severity.PLETAL is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. PLETAL inhibits platelet aggregation in a reversible manner. PLETAL is contraindicated in patients with known or suspected hypersensitivity to any of its components[1] |
References
Adapted from the FDA Package Insert.